Daniele Piomelli Selected Research

Breast Neoplasms (Breast Cancer)

1/2020	Comparative Pharmacokinetics of Δ9-Tetrahydrocannabinol in Adolescent and Adult Male Mice.
9/2014	Structural determinants of peripheral O-arylcarbamate FAAH inhibitors render them dual substrates for Abcb1 and Abcg2 and restrict their access to the brain.
10/2011	The ABC membrane transporter ABCG2 prevents access of FAAH inhibitor URB937 to the central nervous system.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniele Piomelli Research Topics

Disease

64	Pain (Aches) 02/2024 - 01/2004
47	Inflammation (Inflammations) 01/2023 - 01/2005
16	Obesity 03/2024 - 07/2004
14	Hyperalgesia 07/2022 - 02/2006
14	Body Weight (Weight, Body) 01/2021 - 09/2003
11	Neoplasms (Cancer) 11/2021 - 01/2012
10	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 01/2010
7	Migraine Disorders (Migraine) 07/2022 - 12/2015
6	Chronic Pain 10/2021 - 02/2006
6	Substance-Related Disorders (Drug Abuse) 09/2017 - 01/2004
5	Melanoma (Melanoma, Malignant) 10/2021 - 01/2016
5	Wounds and Injuries (Trauma) 12/2020 - 10/2014
5	Neuralgia (Stump Neuralgia) 10/2017 - 02/2006
5	Cognitive Dysfunction 01/2013 - 01/2010
4	Nausea 11/2021 - 02/2007
4	Hypersensitivity (Allergy) 01/2021 - 04/2009
4	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021 - 03/2014
4	Schizophrenia (Dementia Praecox) 01/2019 - 11/2004
3	Hypothermia 01/2024 - 08/2002
3	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 04/2023 - 11/2018
3	Parkinson Disease (Parkinson's Disease) 01/2021 - 09/2003
3	Multiple Sclerosis 01/2021 - 01/2016
3	Chronic Kidney Failure (Chronic Renal Failure) 01/2021 - 10/2019
3	Breast Neoplasms (Breast Cancer) 01/2020 - 10/2011
3	Mood Disorders (Mood Disorder) 01/2020 - 11/2004
3	Ischemia 01/2020 - 08/2002
3	Psychotic Disorders (Schizoaffective Disorder) 01/2019 - 08/2007
3	Edema (Dropsy) 01/2018 - 01/2005
3	Alcoholism (Alcohol Abuse) 01/2016 - 07/2007
3	Marijuana Abuse (Cannabis Abuse) 01/2009 - 12/2002
2	Thinness 03/2024 - 11/2023
2	Dyslipidemias (Dyslipidemia) 03/2024 - 11/2023
2	Virus Diseases (Viral Diseases) 12/2023 - 01/2023
2	COVID-19 01/2022 - 12/2020
2	Peripheral Nervous System Diseases (PNS Diseases) 11/2021 - 09/2005
2	Vomiting 11/2021 - 02/2007

Drug/Important Bio-Agent (IBA)

39	LipidsIBA 02/2024 - 09/2003
37	EndocannabinoidsIBA 07/2022 - 08/2003
29	anandamide (arachidonylethanolamide)IBA 01/2021 - 08/2002
22	CannabinoidsIBA 01/2023 - 11/2002
20	palmidrolIBA 01/2022 - 08/2002
16	fatty-acid amide hydrolase (fatty acid amide hydrolase)IBA 04/2023 - 09/2005
16	oleoylethanolamideIBA 01/2022 - 11/2002
14	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 02/2024 - 07/2008
13	PPAR alphaIBA 11/2016 - 09/2003
12	amidaseIBA 02/2024 - 12/2009
12	Cannabinoid Receptors (Cannabinoid Receptor)IBA 01/2021 - 12/2002
11	N-acylethanolaminesIBA 02/2024 - 12/2009
11	AcidsIBA 02/2024 - 07/2007
11	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)IBA 07/2022 - 02/2006
11	CeramidesIBA 03/2021 - 01/2013
10	EnzymesIBA 10/2021 - 01/2011
10	Fatty Acids (Saturated Fatty Acids)IBA 03/2021 - 08/2002
9	CarrageenanIBA 11/2022 - 01/2005
9	Formaldehyde (Formol)FDA Link 11/2022 - 12/2006
8	URB937IBA 11/2022 - 10/2010
8	AmidesIBA 07/2022 - 08/2002
8	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2009
8	Analgesics (Analgesic Drugs)IBA 01/2018 - 02/2006
7	Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA 11/2010 - 09/2003
6	HydrolasesIBA 02/2024 - 02/2013
6	Acid CeramidaseIBA 10/2021 - 01/2013
6	CB1 Cannabinoid Receptor (CB1 Receptor)IBA 01/2021 - 09/2003
5	Dronabinol (THC)FDA LinkGeneric 03/2024 - 11/2021
5	glyceryl 2-arachidonate (2-arachidonoylglycerol)IBA 01/2018 - 09/2003
5	Monoacylglycerol LipasesIBA 01/2018 - 08/2011
5	Cannabinoid Receptor AgonistsIBA 10/2008 - 09/2003
4	Nitroglycerin (Dynamite)FDA LinkGeneric 07/2022 - 01/2018
4	Cysteine (L-Cysteine)FDA Link 01/2022 - 01/2013
4	5-phenylpentyl N- ((2S,3R)- 2- methyl- 4- oxo- oxetan- 3- yl)carbamateIBA 01/2018 - 09/2012
4	GW 7647IBA 11/2017 - 12/2006
3	Peptides (Polypeptides)IBA 07/2022 - 08/2012
3	CytokinesIBA 07/2022 - 07/2008
3	Therapeutic UsesIBA 12/2021 - 06/2015
3	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2021 - 02/2006
3	SphingolipidsIBA 03/2021 - 01/2015
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 01/2014
3	1-dodecylpyridoxal (PLD)IBA 01/2021 - 03/2015
3	Serine (L-Serine)FDA Link 01/2020 - 02/2013
3	JZL 184IBA 01/2020 - 08/2011
3	URB602IBA 01/2018 - 08/2011
3	Opioid Analgesics (Opioids)IBA 01/2016 - 06/2005
3	Memantine (Namenda)FDA Link 03/2013 - 01/2012
3	Ethanolamine (Colamine)IBA 07/2008 - 01/2005
3	Palmitic Acid (Hexadecanoic Acid)IBA 07/2008 - 01/2005
3	OleylethanolamideIBA 02/2006 - 08/2002
2	CannabidiolIBA 01/2023 - 02/2008
2	CarbamatesIBA 07/2022 - 09/2009
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 07/2022 - 01/2014
2	CholesterolIBA 01/2022 - 01/2010
2	AM 251 (AM251)IBA 01/2021 - 06/2015
2	Transcription Factors (Transcription Factor)IBA 01/2021 - 07/2008
2	Valosin Containing ProteinIBA 01/2021 - 03/2014

Therapy/Procedure

17	Therapeutics 10/2021 - 09/2003
4	Oral Administration 01/2021 - 07/2007
4	Ligation 01/2021 - 02/2006
3	Drug Therapy (Chemotherapy) 11/2021 - 02/2008
3	Topical Administration 09/2015 - 03/2013
2	Analgesia 01/2024 - 02/2006
2	Renal Dialysis (Hemodialysis) 01/2021 - 01/2020